SMARCAL1-AS1: A Potential Drug Target and Biomarker (G107985985)

Target Name: SMARCAL1-AS1

NCBI ID: G107985985

SMARCAL1-AS1

Other Name(s): SMARCAL1 antisense RNA 1

SMARCAL1-AS1: A Potential Drug Target and Biomarker

SMARCAL1-AS1, also known as SMARCAL1 antisense RNA 1, is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and function have made it an attractive target for researchers to investigate, and recent studies have shed light on its potential role in these conditions.

SMARCAL1-AS1 is a member of the SMARCAL1 gene family, which is known for its role in the development and maintenance of stem cells and their associated diseases. The SMARCAL1 gene has four splice variants, SMARCAL1-AS1, SMARCAL1-AS2, SMARCAL1-AS3, and SMARCAL1-AS4, each of which has a unique exonic sequence and gene expression pattern. SMARCAL1-AS1 is the most abundant of the four splice variants and is widely expressed in various tissues and organs, including brain, heart, liver, muscle, and stem cells.

SMARCAL1-AS1 has been shown to play a critical role in the regulation of stem cell proliferation and differentiation. It is a negative regulator of the SMARTCAL1 gene, which encodes a protein involved in cell adhesion and migration. By inhibiting the activity of the SMARTCAL1 protein, SMARCAL1-AS1 has been shown to promote the growth and expansion of stem cells, and to prevent their differentiation into different cell types. This has important implications for the study of stem cell biology and the development of therapeutic approaches for stem cell-based therapies.

In addition to its role in stem cell biology, SMARCAL1-AS1 has also been shown to be involved in the regulation of cellular processes that are important for maintaining tissue homeostasis. It has been shown to play a role in the regulation of cell migration and in the development of tissues and organs, such as the liver and heart. It has also been shown to be involved in the regulation of angiogenesis, the process by which new blood vessels are formed, and in the regulation of inflammation.

SMARCAL1-AS1 has also been shown to be a potential biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its expression has been observed in a variety of cancer types, including breast, ovarian, and colorectal cancer. It has also been shown to be expressed in the brains of individuals with neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases, and has been linked to the development of these conditions.

In addition to its potential clinical applications, SMARCAL1-AS1 is also a promising target for drug development. Its unique structure and function make it an attractive candidate for small molecule inhibitors, which can be used to treat a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Several studies have shown that SMARCAL1-AS1 can be effectively inhibited by small molecules, and that these inhibitors have potential therapeutic applications.

In conclusion, SMARCAL1-AS1 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for several diseases. Its unique structure and function make it an attractive target for small molecule inhibitors, and its potential role in stem cell biology and the regulation of cellular processes important for tissue homeostasis make it an important area of study. Further research is needed to fully understand the potential of SMARCAL1-AS1 as a therapeutic target and biomarker, and to develop effective inhibitors for the treatment of diseases associated with its dysfunction.

Protein Name: SMARCAL1 Antisense RNA 1

The "SMARCAL1-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SMARCAL1-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets